| 000 | 01867 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516134506.0 | ||
| 264 | 0 | _c20140526 | |
| 008 | 201405s 0 0 eng d | ||
| 022 | _a1433-7339 | ||
| 024 | 7 |
_a10.1007/s00520-013-1744-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aXhaard, Aliénor | |
| 245 | 0 | 0 |
_aOutcomes in critically ill chronic lymphocytic leukemia patients. _h[electronic resource] |
| 260 |
_bSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer _cJul 2013 |
||
| 300 |
_a1885-91 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHospital Mortality |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntensive Care Units |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xtherapy |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aEpelboin, Loic | |
| 700 | 1 | _aSchnell, David | |
| 700 | 1 | _aVincent, François | |
| 700 | 1 | _aLevy, Vincent | |
| 700 | 1 | _aMalphettes, Marion | |
| 700 | 1 | _aAzoulay, Elie | |
| 700 | 1 | _aDarmon, Michaël | |
| 773 | 0 |
_tSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer _gvol. 21 _gno. 7 _gp. 1885-91 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00520-013-1744-4 _zAvailable from publisher's website |
| 999 |
_c22506788 _d22506788 |
||